Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous chondrocyte implantation - TiGenix

Drug Profile

Autologous chondrocyte implantation - TiGenix

Alternative Names: ChondroCelect; ChondroCelect-3D; TGX 001; TGX 002; TGX002/FAB002

Latest Information Update: 03 Aug 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TiGenix
  • Class Cell therapies
  • Mechanism of Action Cartilage replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Cartilage disorders

Highest Development Phases

  • Suspended Cartilage disorders

Most Recent Events

  • 31 Jul 2018 TiGenix has been acquired by Takeda
  • 05 Jul 2016 Discontinued - Registered for Cartilage disorders in Liechtenstein, Norway, Iceland, European Union (Parenteral)
  • 05 Jul 2016 Withdrawn for Cartilage disorders in Spain, Finland, Luxembourg, Ireland, Czech Republic, Poland, Portugal, Austria, France, United Kingdom, Belgium, Netherlands, Germany (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top